Drug intelligence / Profile preview

HODO-2305

Development stage: Preclinical
Lead developer: Hyundai Pharmaceutical
Modality: Small Molecules

Overview

HODO-2305 is a small molecule drug candidate currently in preclinical development by Hyundai Pharmaceutical Co., Ltd. for the treatment of cardiovascular diseases. As of the current pipeline status, the specific biological target and mechanism of action have not been publicly disclosed. It is part of Hyundai Pharmaceutical's research and development efforts in the cardiovascular therapeutic area, alongside other candidates like HODO-2224 and HODO-2225. The drug is being developed by the South Korea-based pharmaceutical company, which specializes in various therapeutic areas including cardiovascular, respiratory, endocrinology, and central nervous system disorders.

Beyond the preview

Go deeper on HODO-2305.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HODO-2305.

Explore the full profile